A Phase 3 interventional study of Cariprazine and Placebo in Bipolar Disorder and Depression, sponsored by Forest Laboratories. Completed at 89 sites in 8 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-03-12.
Sponsored by Forest Laboratories (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Bipolar Disorder by AbbVie — 2 open to participants now, 2 under way, none of them phase 3. Bipolar Disorder · AbbVie.
Among the 11 studies in Bipolar Disorder by AbbVie, this one is the 2nd largest by enrollment, is one of 2 that started in 2016, is one of 3 in phase 3, and was the 6th registered.
1,685 studies on the registry are indexed under Bipolar Disorder; 267 are open to participants now.
Browse Bipolar Disorder studies →2 of the 11 studies in Bipolar Disorder by AbbVie are open now, in 1 country. Recruiting first, the newest first:
AbbVie · Sites in United States
Ages 18–65
AbbVie · Sites in United States
Ages 18–65
By country, each count listing its studies:
Of the 205 Bipolar Disorder studies recruiting now, 59 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 37 take children under 18; 50 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 493 is above the median of 64 across 1,279 interventional studies indexed under Bipolar Disorder.
Median enrollment 234 across the 11 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Forest Laboratories, one of the names counted as AbbVie. Under that name alone:
Forest Laboratories is the lead sponsor of 168 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
2 of the studies in Bipolar Disorder by AbbVie that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07071532AbbVieA Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Adult Participants With Bipolar Disorder | 2027-02 |
| NCT06696755AbbVieA Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Bipolar Disorder by AbbVie, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is designed to prospectively confirm the efficacy of a fixed-dose regimen of cariprazine 1.5 milligrams (mg)/day or 3 mg/day compared to placebo for treatment of the depressive episode in participants with bipolar I disorder. The safety and tolerability of the fixed-dose regimens will be evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A verified previous manic or mixed episode. Verification must include one of the following sources:
Exclusion Criteria:
History of meeting criteria for:
Positive result on blood alcohol test or urine drug screen for any prohibited medication. Exception:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Following a 7 to 14 days screening/washout period, cariprazine 1.5 milligrams (mg) capsule, one per day, orally for 2 weeks increased to cariprazine 3.0 mg capsule, one per day orally beginning on Day 15 for 4 weeks.
Drug: Cariprazine
Following a 7 to 14 days screening/washout period, cariprazine 1.5 mg capsule, one per day, orally for 6 weeks.
Drug: Cariprazine
Following a 7 to 14 days screening/washout period, matching placebo capsule, one per day, orally for 6 weeks.
Drug: Placebo
Cariprazine capsule one per day orally.
Also known as: Vraylar
Matching placebo capsule one per day orally.
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS)
MADRS is a 10-item, clinician-rated scale that evaluates the participants depressive symptomatology during the past week. Participants were rated on items assessing feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each of the 10 items was scored on a 7-point scale with a score of 0 reflecting no symptoms and a score of 6 reflecting symptoms of maximum severity for a total possible score of 0 (best) to 60 (worst). A negative change from Baseline indicates improvement. Mixed-effects Model for Repeated Measures (MMRM) with fixed factors (treatment group, pooled study center, and visit), baseline (a covariate), and interactions (treatment group by visit, baseline by visit).
Time frame: Baseline (Week 0) to Week 6
Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Score
CGI-S is a clinician-rated scale that measures the overall severity of a participant's illness in comparison with the severity of other patients the physician has observed. The participant was rated on a scale from 1 to 7, with 1 indicating a "normal state" and 7 indicating "among the most extremely ill patients". A negative change from Baseline indicates improvement. MMRM with fixed factors (treatment group, pooled study center, and visit), baseline (a covariate), and interactions (treatment group by visit, baseline by visit).
Time frame: Baseline (Week 0) to Week 6
| Milestone | Placebo | Cariprazine 1.5 mg | Cariprazine 3.0 mg |
|---|---|---|---|
| Started | 167 | 168 | 158 |
| Safety population : received study drug | 165 | 167 | 158 |
| Intent-to-treat population | 163 | 162 | 153 |
| Completed | 135 | 136 | 128 |
| Not completed | 32 | 32 | 30 |
| Withdrew: Withdrawal of consent | 8 | 6 | 5 |
| Withdrew: Lost to follow-up | 8 | 12 | 7 |
| Withdrew: Adverse event | 5 | 5 | 11 |
| Withdrew: Lack of efficacy | 7 | 1 | 2 |
| Withdrew: Protocol violation | 3 | 4 | 1 |
| Withdrew: Noncompliance with study drug | 1 | 3 | 2 |
| Withdrew: Other miscellaneous reasons | 0 | 1 | 2 |
MADRS is a 10-item, clinician-rated scale that evaluates the participants depressive symptomatology during the past week. Participants were rated on items assessing feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each of the 10 items was scored on a 7-point scale with a score of 0 reflecting no symptoms and a score of 6 reflecting symptoms of maximum severity for a total possible score of 0 (best) to 60 (worst). A negative change from Baseline indicates improvement. Mixed-effects Model for Repeated Measures (MMRM) with fixed factors (treatment group, pooled study center, and visit), baseline (a covariate), and interactions (treatment group by visit, baseline by visit).
| score on a scale | Placebo | Cariprazine 1.5 mg | Cariprazine 3.0 mg |
|---|---|---|---|
| Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) | -12.4 ± 0.75 | -14.8 ± 0.76 | -14.1 ± 0.78 |
CGI-S is a clinician-rated scale that measures the overall severity of a participant's illness in comparison with the severity of other patients the physician has observed. The participant was rated on a scale from 1 to 7, with 1 indicating a "normal state" and 7 indicating "among the most extremely ill patients". A negative change from Baseline indicates improvement. MMRM with fixed factors (treatment group, pooled study center, and visit), baseline (a covariate), and interactions (treatment group by visit, baseline by visit).
| score on a scale | Placebo | Cariprazine 1.5 mg | Cariprazine 3.0 mg |
|---|---|---|---|
| Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Score | -1.2 ± 0.09 | -1.5 ± 0.09 | -1.4 ± 0.09 |
Collected over First dose of study drug up to Day 50. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/165 (0%) | 5/165 (3%) | 36/165 (21.8%) |
| Cariprazine 1.5 mg | 0/167 (0%) | 1/167 (0.6%) | 45/167 (26.9%) |
| Cariprazine 3.0 mg | 0/158 (0%) | 1/158 (0.6%) | 45/158 (28.5%) |
| Event | Placebo | Cariprazine 1.5 mg | Cariprazine 3.0 mg |
|---|---|---|---|
| AbortionPregnancy, puerperium and perinatal conditions | 0/97 | 0/107 | 1/103 |
| Non-cardiac chest painGeneral disorders | 1/165 | 0/167 | 0/158 |
| Lumbar vertebral fractureInjury, poisoning and procedural complications | 1/165 | 0/167 | 0/158 |
| Bipolar disorderPsychiatric disorders | 1/165 | 0/167 | 0/158 |
| ManiaPsychiatric disorders | 1/165 | 0/167 | 0/158 |
| Substance abusePsychiatric disorders | 1/165 | 0/167 | 0/158 |
| DepressionPsychiatric disorders | 0/165 | 1/167 | 0/158 |
| Event | Placebo | Cariprazine 1.5 mg | Cariprazine 3.0 mg |
|---|---|---|---|
| AkathisiaNervous system disorders | 3/165 | 9/167 | 15/158 |
| HeadacheNervous system disorders | 14/165 | 14/167 | 14/158 |
| NauseaGastrointestinal disorders | 5/165 | 13/167 | 8/158 |
| InsomniaPsychiatric disorders | 7/165 | 8/167 | 11/158 |
| RestlessnessPsychiatric disorders | 5/165 | 4/167 | 11/158 |
| AgitationPsychiatric disorders | 10/165 | 3/167 | 7/158 |
| FatigueGeneral disorders | 2/165 | 9/167 | 5/158 |
Randomized Population consisted of all participants in the Screened Population who were randomized to a treatment group in the study.
| Age, Continuous(years) | Placebo | Cariprazine 1.5 mg | Cariprazine 3.0 mg | Total |
|---|---|---|---|---|
| Mean | 44.4 ± 11.6 | 42.2 ± 12.0 | 43.9 ± 11.8 | 43.5 ± 11.8 |
| Sex: Female, Male(Participants) | Placebo | Cariprazine 1.5 mg | Cariprazine 3.0 mg | Total |
|---|---|---|---|---|
| Female | 99 | 107 | 103 | 309 |
| Male | 68 | 61 | 55 | 184 |
| Race/Ethnicity, Customized(Participants) | Placebo | Cariprazine 1.5 mg | Cariprazine 3.0 mg | Total |
|---|---|---|---|---|
| White | 121 | 121 | 117 | 359 |
| Black or African American | 46 | 41 | 39 | 126 |
| Asian | 0 | 3 | 2 | 5 |
| Multiple Races | 0 | 3 | 0 | 3 |
| Race/Ethnicity, Customized(Participants) | Placebo | Cariprazine 1.5 mg | Cariprazine 3.0 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 18 | 22 | 15 | 55 |
| Not Hispanic or Latino | 149 | 146 | 143 | 438 |
| Montgomery-Åsberg Depression Rating Scale (MADRS)(score on a scale) | Placebo | Cariprazine 1.5 mg | Cariprazine 3.0 mg | Total |
|---|---|---|---|---|
| Mean | 31.4 ± 4.5 | 31.5 ± 4.3 | 31.5 ± 4.8 | 31.5 ± 4.5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2016 to primary completion in Jan 2018, 21 months.
Results were first posted in Feb 2019, 1 year after primary completion.
Of 29 industry-sponsored phase 3 interventional studies under Bipolar Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 49. This study's 21 months is below that.
Counting every sponsor, half of 43 studies reached it within 37 months; a quarter within 21 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cariprazine